Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Genomind, LLC
Age
18–65
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
age 18-65
written informed consent
diagnosis of non-psychotic major depression as determined by study
clinician/current medical prescriber, and mood disorder diagnosis confirmed by PHQ-9
QIDS-SR score of at least 10 (i.e., moderate depression) at initial visit
failure of at least 1 prior adequate trial of a standard antidepressant (by ATRQ criteria - i.e., 6 weeks at adequate dose)
You may not be if
psychotic features in the current episode, based upon clinical assessment
4 or more failed pharmacologic interventions in the current major depressive episode \[response rates for these subjects is likely to be extremely low and would require a substantially larger-scale study to identify treatment effects\]
current substance use disorder other than nicotine which based upon clinical assessment requires inpatient or outpatient detoxification
pregnant women or women of child bearing potential who are not using a medically accepted means of contraception (to include oral contraceptive or implant, condom, diaphragm, spermicide, intrauterine device, tubal ligation, or partner with vasectomy)
women who are breastfeeding
serious suicide or homicide risk, as assessed by evaluating clinician
other unstable medical illness including cardiovascular, hepatic, renal, respiratory, endocrine, neurological, or hematological disease, based on review of medical history, physical examination, and screening laboratory tests
patients who have taken an investigational psychotropic drug within the last 3 months
Clareo Health | Pharmacogenomics for Antidepressant Guidance and Education 1 (PAGE-1_AG1)
